CLINICAL TRIALS PROFILE FOR MIDODRINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for MIDODRINE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004268 ↗ | Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension | Completed | Roberts Pharmaceutical | Phase 2 | 2001-04-01 | OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension. II. Assess the quality of life in these patients with this treatment regimen. |
| NCT00004268 ↗ | Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension | Completed | National Center for Research Resources (NCRR) | Phase 2 | 2001-04-01 | OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension. II. Assess the quality of life in these patients with this treatment regimen. |
| NCT00004479 ↗ | Randomized Study of Midodrine, an Alpha Adrenergic Agonist, in Patients With Neurally Mediated Syncope | Completed | Icahn School of Medicine at Mount Sinai | N/A | 1999-03-01 | OBJECTIVES: Determine the efficacy of midodrine, a selective alpha 1 adrenergic agonist, in preventing neurally mediated syncope. |
| NCT00046163 ↗ | A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension | Terminated | Shire | Phase 4 | 2002-09-05 | We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright position) due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension). Symptoms of low blood pressure include dizziness, lightheadedness, changes in vision and generalized weakness upon standing. The main effect of the drug being studied is to increase blood pressure in the upright position so symptoms will decrease. The purpose of this clinical study is to further assess the clinical effect of high dose midodrine hydrochloride (ProAmatine®), an approved treatment for orthostatic hypotension. During the course of the study, participants will receive either ProAmatine® or a placebo. Assessments will be made using questionnaires that measure symptom and activity levels. Blood pressure in the lying down, sitting and standing positions will be measured. Patients will also complete standing time assessments. They will be asked to remain standing without moving until they feel sufficiently lightheaded, or dizzy, or feel faint so that they would feel more comfortable sitting down. |
| NCT00046475 ↗ | A Study for Patients With Neurogenic Orthostatic Hypotension | Completed | Shire | Phase 4 | 1997-12-01 | We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright position) due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension). Symptoms of low blood pressure include dizziness, lightheadedness, changes in vision and generalized weakness upon standing. The main effect of the drug being studied is to increase blood pressure in the upright position so symptoms will decrease. The purpose of this clinical study is to further assess the clinical benefit of midodrine hydrochloride (ProAmatine®), an approved treatment for orthostatic hypotension. During the course of the study, participants will receive either ProAmatine® or a placebo. Assessments will be made using questionnaires that measure symptom and activity levels. Blood pressure in the lying down and standing positions will be measured at each visit. |
| NCT00108355 ↗ | Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis | Completed | US Department of Veterans Affairs | Phase 4 | 2003-12-01 | This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites. |
| NCT00108355 ↗ | Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis | Completed | VA Office of Research and Development | Phase 4 | 2003-12-01 | This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MIDODRINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for MIDODRINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for MIDODRINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for MIDODRINE HYDROCHLORIDE
Sponsor Name
